Glycopyrrolate (injection)
گلیکوپیرولات (تزریقی)
🍽️ Alimentary Tract And MetabolismAnticholinergic (antimuscarinic)
Market / country: 🇺🇸 USA
Robinul (US)
🧮 Dose calculator
General anaesthesia and premedication (adjunct) · Regimen source: FDA Glycopyrrolate inj · Dosage and Administration
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity; for prolonged peptic-ulcer therapy: glaucoma, obstructive uropathy, GI obstruction, paralytic ileus, intestinal atony, unstable cardiovascular status, severe ulcerative colitis, myasthenia gravis. FDA Glycopyrrolate inj · Contraindications
Warnings
- • Glaucoma; benzyl alcohol (toxicity and kernicterus in preterm neonates). FDA Glycopyrrolate inj · Warnings
Formulations
- 0.2 mg/mL vial (IM or IV) — injection 🇺🇸 USA FDA Glycopyrrolate inj · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Glycopyrrolate inj · Pregnancy
“Teratogenic Effects Pregnancy Category B: Reproduction studies with glycopyrrolate were performed in rats at a dietary dose of approximately 65 mg/kg/day (exposure was approximately 320 times the maximum recommended daily human dose of 2 mg on a mg/m 2 basis) and rabbits at intramuscular doses of up to 0.5 mg/kg/day …”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Glycopyrrolate inj · Nursing Mothers
“Because many drugs are excreted in human milk, caution should be exercised when glycopyrrolate injection is administered to a nursing woman.”
- 👶 ChildrenUse with caution
Label: paediatric pre-anaesthetic dosing (0.004 mg/kg); not in neonates under 1 month (benzyl alcohol); not established for peptic ulcer. FDA Glycopyrrolate inj · Pediatric Use
“Due to its benzyl alcohol content, glycopyrrolate injection should not be used in neonates, i.e., patients less than 1 month of age.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Glycopyrrolate inj · Geriatric Use
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA089335
- DailyMed (FDA label)FDA Glycopyrrolate inj
- MedlinePlus (NIH)GlycopyrrolateGlycopyrrolate Oral Inhalation
- WHO ATC/DDDA03AB02
- Darooyab (Iran)Glycopyrronium
🇮🇷 Registered in Iran Darooyab · G-892/Glycopyrronium
Dosage forms with Iranian generic codes, per Darooyab.
- 14901 · GLYCOPYRRONIUM BROMIDE 0.2MG/ML AMP · آمپول گلیکوپیررونیوم بروماید ۰٫۲ میلیگرم / میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Glycopyrrolate inj · How SuppliedFDA Glycopyrrolate inj · Dosage and AdministrationFDA Glycopyrrolate inj · ContraindicationsFDA Glycopyrrolate inj · WarningsFDA Glycopyrrolate inj · PregnancyFDA Glycopyrrolate inj · Nursing MothersFDA Glycopyrrolate inj · Pediatric UseFDA Glycopyrrolate inj · Geriatric UseFDA Glycopyrrolate inj · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-892/Glycopyrronium
- Clinical review⚠ Unverified